Related Experiment Video
Updated: May 26, 2026
10:41
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
Effect of clovoxamine fumarate on the electrocardiogram
1Department of Psychiatry, Royal South Hants Hospital, Southampton SO9 4PE, UK.
Journal of Psychopharmacology (Oxford, England)
|December 14, 2011
Summary
Clovoxamine, an antidepressant, showed no significant impact on electrocardiograms (ECG) in patients with depression. This study indicates clovoxamine is safe for the heart in therapeutic doses for patients without pre-existing cardiovascular conditions.
Area of Science:
- Pharmacology
- Cardiology
- Psychiatry
Background:
- Clovoxamine is an antidepressant affecting noradrenaline and serotonin.
- Electrocardiographic (ECG) effects of antidepressants require careful evaluation.
- No prior studies extensively documented clovoxamine's cardiac safety profile.
Purpose of the Study:
- To investigate the electrocardiographic effects of clovoxamine.
- To determine if clovoxamine alters cardiac electrical activity in patients with depression.
- To assess the cardiovascular safety of clovoxamine treatment.
Main Methods:
- 28 patients with depressive illness were enrolled.
- High-speed electrocardiograms (ECG) were recorded before and after 4 weeks of treatment.
- Patients received either clovoxamine or placebo in a blinded manner.
Main Results:
- No statistically significant changes were observed in sinus cycle length, PR, QRS, or QTc intervals.
- T-wave height remained unchanged after treatment with clovoxamine or placebo.
- Clovoxamine demonstrated no clinically significant ECG alterations.
Conclusions:
- Clovoxamine does not produce clinically important adverse effects on the ECG.
- The antidepressant is considered safe for cardiac function in therapeutic doses.
- Patients without significant physical disease can be treated with clovoxamine without cardiac concern.
More Related Videos
Related Concept Videos
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
01:29Electrocardiogram
An electrocardiogram (ECG or EKG) is a critical diagnostic tool that records the electrical signals produced by the heart during each heartbeat. This recording is achieved through electrodes placed strategically on the arms, legs, and chest. The electrocardiograph amplifies these signals and produces 12 distinct tracings, offering a comprehensive understanding of the heart's electrical activity.
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and the T...
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and the T...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...